MOTS-c in Australia: Mitochondrial Research Guide & Where to Buy

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded within the 12S ribosomal RNA gene of mitochondrial DNA. First identified by Changhan Lee and colleagues at the University of Southern California and published in Nature Medicine in 2015, it belongs to a rare class of bioactive peptides encoded in mitochondrial, rather than nuclear, DNA.

Under conditions of metabolic stress (including nutrient excess, folate stress, and reactive oxygen species accumulation) MOTS-c translocates from the mitochondrial matrix to the nucleus. There it regulates gene expression linked to glucose homeostasis, lipid oxidation, and cellular stress adaptation. This retrograde communication from mitochondria to nucleus makes MOTS-c structurally and functionally unlike any nuclear-encoded peptide in current research.

Key mechanismMOTS-c activates the AMPK pathway, which promotes GLUT4 translocation to the cell membrane, increases glucose uptake independent of insulin, and shifts fuel utilisation toward fatty acid oxidation. These downstream effects form the basis of its metabolic and insulin-sensitivity research interest.

Two interconnected patterns from published research define MOTS-c's role in ageing:

• Plasma decline with age, cross-sectional human studies have found that circulating MOTS-c levels fall progressively with advancing age, mirroring declines in insulin sensitivity and physical capacity. Notably, studies of centenarian populations have found elevated MOTS-c relative to age-matched controls, generating longevity research interest
• Blunted exercise response (in young humans and mice, plasma MOTS-c rises transiently following high-intensity exercise, acting as an exercise-inducible mitohormone. The 2022 Nature Aging study (Kim KH et al.) demonstrated this response is significantly attenuated in aged subjects) and that exogenous MOTS-c administration partially restored exercise tolerance in aged mouse models

Research contextThe attenuation of exercise-induced MOTS-c signalling with age is thought to contribute to the progressive decline in metabolic resilience characteristic of ageing. Exogenous MOTS-c research aims to explore whether restoring this signal can influence age-related metabolic and physical decline in preclinical models.

MOTS-c and SS-31 (Elamipretide) are the two most-studied mitochondrial-targeted research peptides, but they act via completely different mechanisms. See also: SS-31 research guide →

MOTS-c is supplied as lyophilised powder and must be reconstituted with bacteriostatic water before laboratory use. Standard volumes for a 10mg vial:

Inject bacteriostatic water slowly down the inside wall of the vial, do not inject directly onto the powder. Swirl gently; MOTS-c dissolves readily. Store reconstituted solution at 2–8°C and use within 28 days. OzPeps stocks bacteriostatic water 10mL → in the supplies section. Full protocol: peptide reconstitution guide →

What is MOTS-c's amino acid sequence?

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR. It is one of the few known bioactive peptides encoded entirely within mitochondrial, rather than nuclear, DNA.

How does MOTS-c differ from other metabolic research peptides?

Unlike GLP-1 analogues (semaglutide, retatrutide) which act on gut-derived hormone receptors, MOTS-c works intracellularly via AMPK activation and nuclear gene regulation. It is not a receptor agonist, it modulates cellular energy sensing directly. This makes it a distinct mechanism in the metabolic research space.

Do MOTS-c levels decline with age?

Yes. Cross-sectional human studies consistently show circulating plasma MOTS-c falls with advancing age, correlating with markers of insulin resistance and reduced physical capacity. Centenarian cohorts have shown relatively elevated MOTS-c compared to age-matched non-centenarian controls, making it a longevity biomarker of research interest.

What concentrations are used in published MOTS-c research?

Mouse model studies have used 0.5 mg/kg/day i.p. (Lee et al. 2015 insulin resistance work) up to 5–15 mg/kg in exercise and ageing studies. No established human dosing exists, all human data is observational (plasma level measurements), not interventional. MOTS-c is not approved for human use.

Can MOTS-c be combined with SS-31 in research protocols?

MOTS-c and SS-31 target different aspects of mitochondrial biology, MOTS-c works via nuclear retrograde signalling while SS-31 acts directly on the inner mitochondrial membrane. Some research groups use both compounds in combination protocols studying mitochondrial dysfunction in ageing models. OzPeps stocks both: SS-31 10mg →

Most AMPK activators raise the cellular AMP:ATP ratio, exercise depletes ATP mechanically, metformin inhibits Complex I of the electron transport chain, and ischaemia causes acute ATP depletion. MOTS-c operates via a mechanistically distinct upstream route: targeted disruption of the one-carbon folate cycle.

The characterised sequence of events:

1. Folate cycle inhibition, MOTS-c inhibits key enzymatic steps in the de novo purine synthesis branch of one-carbon folate metabolism, causing upstream accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide)
2. ZMP mimics AMP at AMPK (AICAR is phosphorylated to ZMP, which binds the γ-subunit of AMPK in the same allosteric site as AMP. ZMP activates AMPK and protects it from dephosphorylation) without requiring actual ATP depletion
3. Downstream metabolic reprogramming, activated AMPK phosphorylates ACC (inhibiting lipid synthesis), promotes GLUT4 translocation to the plasma membrane (increasing glucose uptake), activates PGC-1α (driving mitochondrial biogenesis), and phosphorylates TSC2 (inhibiting mTORC1)

Why this pathway matters for researchMOTS-c can activate AMPK under conditions of normal cellular energy status, it creates an upstream signal that AMPK interprets as energy deficit without requiring actual ATP depletion. This distinguishes it from exercise, metformin, and ischaemia-mediated AMPK activation. In preclinical models, MOTS-c metabolic effects do not appear to impair acute energy production, unlike Complex I-inhibiting AMPK activators.

This mechanism was characterised in the original Lee et al. 2015 Cell Metabolism paper. The folate cycle disruption route also provides a rationale for MOTS-c's sensitivity to folate stress states, periods of high cellular folate demand amplify sensitivity to MOTS-c's folate cycle inhibition, linking mitochondrial-derived signalling to whole-cell metabolic context.

Beyond its metabolic research context, MOTS-c has been investigated for anti-inflammatory properties across several preclinical model systems. These effects are partly downstream of AMPK activation but extend into distinct inflammatory signalling cascades:

mTORC1 suppression: AMPK activation by MOTS-c inhibits mTORC1 via phosphorylation of the TSC1/TSC2 complex. Chronic mTORC1 hyperactivation is a feature of obesity, insulin resistance, and metabolic ageing. Suppression by MOTS-c in HFD mouse models has been associated with reduced inflammatory marker expression in adipose and hepatic tissue, supporting a link between MOTS-c administration and attenuated metabolic inflammation.

NF-κB modulation: Several preclinical studies report that MOTS-c reduces NF-κB transcriptional activity in metabolically stressed tissue. NF-κB drives expression of pro-inflammatory cytokines including IL-6, TNF-α, IL-1β, and MCP-1. Reductions in these markers following MOTS-c administration have been documented in HFD and LPS challenge models. Whether NF-κB suppression is entirely AMPK-dependent or reflects a parallel pathway remains under active investigation.

Sepsis models: An emergent area is MOTS-c's anti-inflammatory profile in sepsis. Studies using LPS-induced systemic inflammatory response in mice have demonstrated that MOTS-c reduces the cytokine storm response, preserves mitochondrial function in organ tissue, and improves survival metrics in both prophylactic and post-exposure protocols. The mitochondrial dysfunction component of sepsis pathology, where respiratory chain failure in organ tissue contributes to multi-organ failure, is the proposed primary mechanism.

Osteoclastogenesis research: Preclinical cell culture and mouse studies have found MOTS-c inhibits RANKL-induced osteoclast differentiation, reducing bone resorption marker expression in osteoporosis models. Evidence is early-stage and restricted to preclinical data; no clinical research on this application exists.

OzPeps is an Australia-based peptide supplier stocking research-grade MOTS-c 10mg lyophilised vials with domestic shipping (1–3 business days Australia-wide). All peptides are supplied as lyophilised powder for laboratory reconstitution.

• Product: MOTS-c 10mg, lyophilised powder, single vial
• Shipping: Domestic Australia, 1–3 business days
• Payment: Cryptocurrency (Bitcoin, Monero, Litecoin)
• Supplies: Bacteriostatic water, insulin syringes, and alcohol swabs also available

View MOTS-c 10mg stock and current pricing →

MOTS-c is sold strictly for in-vitro laboratory research. Not TGA-approved. Not for human or animal consumption.